Vertex Pharmaceuticals Net Tangible Assets

The latest net tangible assets for VRTX is $19B as of March 2026. That compares with $23B in the prior-year period — down 15.4% year over year. Investors often review this figure alongside Vertex Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, VRTX's net tangible assets moved from $23B to $19B — a 15.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vertex Pharmaceuticals's operating scale or balance-sheet position.

A net tangible assets figure of $19B for VRTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting VRTX's net tangible assets ($19B), review year-over-year change from $23B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Vertex Pharmaceuticals's net tangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.